NeoVentures Biotechnology Europe Partners with Ombion Biomarker discovery has driven major advances in healthcare, but most traditional approaches rely on animal-produced antibodies. Researchers generate these antibodies by introducing human recombinant proteins into animals and harvesting… 

NeoVentures Biotechnology Europe has joined NVIDIA Inception, a program designed to help startups evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA. At NVB Europe, we’ve developed the Aptamarker Platform,… 

NeoVentures Biotechnology Europe and IRD-Montpellier Launch Strategic Partnership in Single-Cell Proteomics The Institut de Recherche pour le Développement, Délégation Régionale Occitanie (IRD-Montpellier), and NeoVentures Biotechnology Europe (NVBE) are proud to announce a strategic partnership to… 

NeoNeuro Receives Investment from ADDF NeoNeuro announced today that the Alzheimer’s Drug Discovery Foundation (ADDF) invested in the company through its Diagnostics Accelerator. The initiative aims to fast-track development of novel biomarkers for early detection… 

NeoNeuro Partners with the INSIGHT Cohort NeoNeuro SAS has entered into a collaboration under the leadership of Professor Harald Hampel to work with the INSIGHT cohort for the application of the Aptamarker Platform to pre-AD samples.… 

NeoNeuro Collaborates with the AIBL Study NeoNeuro SAS  is pleased to announce a collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL)  group. The collaboration is focused on exploring the potential…